Related Experiment Video

Updated: Apr 30, 2026

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

12.4K

The association between the LPA gene polymorphism and coronary artery disease in Chinese Han population

Zi-Kai Song1, Hai-Di Wu1, Hong-Yan Cao1

  • 1Department of Cardiology, The First Hospital of Jilin University, 3302 JiLin Street, Changchun 130031, China.

Biomed Research International
|May 3, 2014
PubMed

Insights

Genetic variations in the LPA gene, specifically rs9364559, are linked to coronary artery disease (CAD) risk in the Chinese Han population. Certain LPA gene haplotypes containing rs9364559 also increase CAD susceptibility.

Area of Science:

  • Genetics
  • Cardiovascular Disease Research
  • Population Studies

Background:

  • Lipoprotein(a) [Lp(a)] is a recognized independent risk factor for coronary artery disease (CAD).
  • The LPA gene encodes apolipoprotein(a), a key component of Lp(a), and its variations have been implicated in CAD risk.

Purpose of the Study:

  • To investigate the association between polymorphisms in the LPA gene and the risk of CAD.
  • To analyze specific single nucleotide polymorphisms (SNPs) and haplotypes within the LPA gene in a Chinese Han population.

Main Methods:

  • Genotyping of five LPA gene SNPs (rs1367211, rs3127596, rs6415085, rs9347438, and rs9364559) using Sequenom MassARRAY.
  • Case-control study design involving 560 CAD patients and 531 non-CAD controls of Chinese Han ancestry.
  • Haplotype analysis to assess combined SNP effects on CAD risk.

Main Results:

  • The rs9364559 polymorphism in the LPA gene showed a significant association with CAD risk at both allele (P = 0.046) and genotype (P = 0.026) levels.
  • The minor allele (G) of rs9364559 was found at a higher frequency in the CAD patient group compared to the control group.
  • Haplotype analysis revealed that four specific haplotypes incorporating rs9364559-G were associated with an elevated risk of developing CAD.

Conclusions:

  • The rs9364559 polymorphism within the LPA gene may play a role in the pathogenesis of coronary artery disease.
  • Individuals carrying specific haplotypes of the LPA gene, particularly those including rs9364559-G, may face a higher risk of CAD in this population.

Related Concept Videos

Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
14.6K
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
12.6K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
138
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.8K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
159